Sugentech, Inc. Logo

Sugentech, Inc.

An in-vitro diagnostics company that develops and commercializes diagnostic solutions.

253840 | KO

Overview

Corporate Details

ISIN(s):
KR7253840003
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노2로 206 사무동2층 수젠텍, 대전광역시

Description

Sugentech, Inc. is an in-vitro diagnostics (IVD) company that develops and commercializes diagnostic solutions by integrating biotechnology, nanotechnology, and information technology. The company's product portfolio serves diverse healthcare settings, from large hospitals and laboratories to smaller clinics and home users. Key offerings include automated multi-immunoblot systems, point-of-care testing (POCT) platforms, and self-diagnostic kits for personal use, such as ovulation and pregnancy tests. Sugentech leverages proprietary technologies in developing high-level antibodies and advanced nanoparticles to create highly sensitive and precise immunochemical assays, underpinning its digital healthcare diagnostic platform for personalized medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-03-17 00:00
[기재정정]의결권대리행사권유참고서류
Korean 248.2 KB
2022-03-16 00:00
주주총회소집결의
Korean 18.8 KB
2022-03-16 00:00
주주총회집중일개최사유신고
Korean 4.7 KB
2022-03-16 00:00
주주총회소집공고
Korean 425.5 KB
2022-03-15 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 12.6 KB
2022-03-08 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 12.7 KB
2022-02-28 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2022-02-17 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.1 KB
2022-01-06 00:00
단일판매ㆍ공급계약체결
Korean 9.5 KB
2021-12-30 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 12.7 KB
2021-12-14 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2021-11-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2021-11-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2021-11-15 00:00
단일판매ㆍ공급계약체결
Korean 9.6 KB
2021-11-15 00:00
분기보고서 (2021.09)
Korean 2.0 MB

Automate Your Workflow. Get a real-time feed of all Sugentech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sugentech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sugentech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.